In Vivo Efficacy of Replication Stress Targeted Therapy in Ewing Sarcoma

Ewing sarcoma (EwS) is a rare pediatric cancer of the bone and soft tissue. Although the five-year survival rate of localized disease is relatively high, outcomes for patients with metastatic or recurrent disease are poor. Additionally, aggressive chemotherapy use in pediatric populations increases the risk of secondary complications. We have previously demonstrated the success of in vitro targeting of replication stress in EwS. Here, we evaluate this combination in vivo. Cell division cycle 7 (CDC7), also known as DBF4-dependent kinase (DDK), and WEE1 kinase inhibition was compared to EwS standard-of-care regimens. NSG mice received subcutaneous injections of the cell lines TC-32, A673, or RD-ES, or engraftments of SJEWS001321_X1 patient derived xenograft tissue, followed by three cycles of treatment. Arms with DDK inhibition (DDKi) + WEE1 inhibition + irinotecan (triplet arm) delivered with an optimized schedule were significantly more effective in acute reduction of tumor volume with durable reduction of volume compared to all other groups in TC-32 cell line derived xenografts (p < 0.01). Triplet arms with full dose or half dose irinotecan were equally effective (p > 0.05), suggesting that this strategy allows chemotherapeutic de-escalation. In an EwS patient derived xenograft, arms with DDKi + irinotecan were as effective as the triplet arm (p > 0.05). Replication stress targeted therapy with a chemotherapy backbone is more efficacious than comparable standard-of-care therapies and allows dose de-escalation of chemotherapy. Thus, this strategy is a promising potential therapeutic combination in Ewing sarcoma and should be considered for advancement to the clinic.

Authors

Institutions

Publication Details

Journal
Molecular Cancer Therapeutics
Published
2026-11-18
DOI
https://doi.org/10.1158/1535-7163.mct-25-1368
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

In Vivo Efficacy of Replication Stress Targeted Therapy in Ewing Sarcoma

Emily E. Mackey, Sarah Gawlak, Emily Isenhart, Ajay Kumar Gupta et al.
2 links
Molecular Cancer Therapeutics
Sarcoma Diagnosis and Treatment
article

In Vivo Efficacy of Replication Stress Targeted Therapy in Ewing Sarcoma

Emily E. Mackey, Sarah Gawlak, Emily Isenhart, Ajay Kumar Gupta, Joyce Ellen Ohm, Bryan M. Gillard
article en

Abstract

Ewing sarcoma (EwS) is a rare pediatric cancer of the bone and soft tissue. Although the five-year survival rate of localized disease is relatively high, outcomes for patients with metastatic or recurrent disease are poor. Additionally, aggressive chemotherapy use in pediatric populations increases the risk of secondary complications. We have previously demonstrated the success of in vitro targeting of replication stress in EwS. Here, we evaluate this combination in vivo. Cell division cycle 7 (CDC7), also known as DBF4-dependent kinase (DDK), and WEE1 kinase inhibition was compared to EwS standard-of-care regimens. NSG mice received subcutaneous injections of the cell lines TC-32, A673, or RD-ES, or engraftments of SJEWS001321_X1 patient derived xenograft tissue, followed by three cycles of treatment. Arms with DDK inhibition (DDKi) + WEE1 inhibition + irinotecan (triplet arm) delivered with an optimized schedule were significantly more effective in acute reduction of tumor volume with durable reduction of volume compared to all other groups in TC-32 cell line derived xenografts (p < 0.01). Triplet arms with full dose or half dose irinotecan were equally effective (p > 0.05), suggesting that this strategy allows chemotherapeutic de-escalation. In an EwS patient derived xenograft, arms with DDKi + irinotecan were as effective as the triplet arm (p > 0.05). Replication stress targeted therapy with a chemotherapy backbone is more efficacious than comparable standard-of-care therapies and allows dose de-escalation of chemotherapy. Thus, this strategy is a promising potential therapeutic combination in Ewing sarcoma and should be considered for advancement to the clinic.

Molecular Cancer Therapeutics
Roswell Park Comprehensive Cancer Center (US)
Good health and well-being
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon